PetVivo Holdings, Inc.

What they do

PetVivo develops, manufactures and commercializes biomaterial-based medical devices and therapeutics for animals, operating as one segment from Edina, Minnesota. Its lead product, Spryng with OsteoCushion Technology, is a veterinarian-administered intra-articular injection of collagen, elastin and heparin particles intended to act as a bio-integrative scaffold in affected joints for lameness and osteoarthritis in dogs and horses. The company says it has a pipeline of seventeen products, ten issued patents (six U.S., four foreign), two U.S. patent applications and six trade secrets. Commercialization of Spryng began in the quarter ended March 31, 2022.

Revenue drivers

• Spryng with OsteoCushion Technology — The lead and only product identified in the filings as commercialized, sold as a veterinarian-administered intra-articular injection for dogs and horses; it is the source of essentially all reported revenue.
• Licensing — The company states it is focused on manufacturing, commercialization and licensing of devices and therapeutics for animals; no licensing revenue figure is disclosed in the excerpts.
• Product pipeline — Seventeen products are described as in the pipeline for animals and humans, but the filings do not attribute any current revenue to them.

Recent performance

Annual revenue has been flat at roughly $1.1 million in fiscal 2025 and fiscal 2026, up from $968,706 in fiscal 2024 and $917,162 in fiscal 2023. Net losses remain large: $10.5 million in fiscal 2026, $8.4 million in fiscal 2025, and $11.0 million in fiscal 2024. Operating cash use was $6.1 million in fiscal 2026 versus $5.3 million in fiscal 2025. Quarterly revenue for the four quarters ended June 30, 2026 ranged from $254,715 (March 2026) to $337,572 (June 2026). At June 30, 2026, total assets were $2.7 million, total liabilities $1.3 million and shareholder equity $1.4 million.

Strategy

Management's stated approach is to leverage technology originally developed for human biomedical applications to commercialize treatments for horses and companion animals in a capital- and time-efficient way. The company continues to position Spryng as an alternative to symptom-only treatments such as NSAIDs, steroid injections and hyaluronic acid injections, emphasizing that its particles mimic natural cartilage composition and structure. It points to a large addressable market, citing osteoarthritis in approximately 14 million dogs and 1 million horses within an $11 billion companion animal veterinary care and product sales market. Financing activity has been continuous: eight 8-K events since March 2026 include material agreements and unregistered equity sales, plus an accountant change and a terminated material agreement.

Risks

• Persistent losses and cash burn — PetVivo lost $10.5 million in fiscal 2026 and used $6.1 million of operating cash, while revenue stayed near $1.1 million, so the business depends on external financing.
• Thin balance sheet — At June 30, 2026, total assets were only $2.7 million against $1.3 million of liabilities, leaving limited cushion; cash and equivalents were reported at just $28,891 as of December 31, 2024.
• Single-product concentration — Revenue depends on Spryng, the only product the filings describe as commercialized, leaving results exposed to adoption by veterinarians and clinics.
• Financing and governance events — Since March 2026 the company has reported repeated material agreements and unregistered equity sales, a change of accountants in July 2026, and termination of a material agreement on July 29, 2026, alongside its move from Nasdaq to the OTCQX market.

Outlook

The filing excerpts provided do not include management's specific forward guidance or liquidity projections. The company's stated direction remains commercializing and licensing veterinary products, particularly Spryng, while drawing on human biomedical technology. Given flat revenue and recurring losses, future funding and adoption of Spryng are the main variables the disclosed material speaks to.